| Year |
Citation |
Score |
| 2022 |
Clevenger CV, Rui H. Breast cancer and prolactin - new mechanisms and models. Endocrinology. PMID 35922139 DOI: 10.1210/endocr/bqac122 |
0.345 |
|
| 2021 |
Geethadevi A, Nair A, Parashar D, Ku Z, Xiong W, Deng H, Li Y, George J, McAllister DM, Sun Y, Kadamberi IP, Gupta P, Dwinell MB, Bradley WH, Rader JS, ... Rui H, et al. Oncostatin M Receptor-targeted antibodies suppress STAT3 signaling and inhibit ovarian cancer growth. Cancer Research. PMID 34380633 DOI: 10.1158/0008-5472.CAN-21-0483 |
0.32 |
|
| 2021 |
Rädler PD, Wehde BL, Triplett AA, Shrestha H, Shepherd JH, Pfefferle AD, Rui H, Cardiff RD, Perou CM, Wagner KU. Highly metastatic claudin-low mammary cancers can originate from luminal epithelial cells. Nature Communications. 12: 3742. PMID 34145248 DOI: 10.1038/s41467-021-23957-5 |
0.34 |
|
| 2020 |
Cho C, Mukherjee R, Peck AR, Sun Y, McBrearty N, Katlinski KV, Gui J, Govindaraju PK, Puré E, Rui H, Fuchs SY. Cancer-associated fibroblasts downregulate type I interferon receptor to stimulate intratumoral stromagenesis. Oncogene. PMID 32807917 DOI: 10.1038/S41388-020-01424-7 |
0.371 |
|
| 2020 |
Rau A, Manansala R, Flister MJ, Rui H, Jaffrézic F, Laloë D, Auer PL. Individualized multi-omic pathway deviation scores using multiple factor analysis. Biostatistics (Oxford, England). PMID 32766691 DOI: 10.1093/Biostatistics/Kxaa029 |
0.341 |
|
| 2020 |
Odnokoz O, Yu P, Peck AR, Sun Y, Kovatich AJ, Hooke JA, Hu H, Mitchell EP, Rui H, Fuchs SY. Malignant cell-specific pro-tumorigenic role of type I interferon receptor in breast cancers. Cancer Biology & Therapy. 1-8. PMID 32378445 DOI: 10.1080/15384047.2020.1750297 |
0.461 |
|
| 2020 |
Morita Y, Leslie M, Kameyama H, Lokesh GLR, Ichimura N, Davis R, Hills N, Hasan N, Zhang R, Kondo Y, Gorenstein DG, Volk DE, Chervoneva I, Rui H, Tanaka T. Functional Blockade of E-Selectin in Tumor-Associated Vessels Enhances Anti-Tumor Effect of Doxorubicin in Breast Cancer. Cancers. 12. PMID 32204492 DOI: 10.3390/Cancers12030725 |
0.341 |
|
| 2020 |
Pestell RG, Cristofanilli M, Rui H, Jiao X, Wang M. Abstract PD4-04: Leronlimab, a humanized monoclonal antibody to CCR5, restrains breast cancer metastasis and enhances cell death induced by DNA damaging chemotherapies Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-Pd4-04 |
0.464 |
|
| 2020 |
Chaudhary LN, Jorns J, Gonyo M, Kong A, Peck AR, Sun Y, Bergom C, Banarjee A, Chitambar C, Rui H. Abstract P6-04-23: HER2 up-regulation with neoadjuvant endocrine therapy in patients with hormone receptor-positive, HER2-negative breast cancer Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P6-04-23 |
0.414 |
|
| 2020 |
Liu J, Fantacone-Campbell JL, Kovatich AJ, Deyarmin B, Mostoller BJ, Hooke JA, Rui H, Shriver CD, Hu H. Abstract P2-18-03: Breast cancer treatment and association with clinicopathologic features in TCGA Cancer Research. DOI: 10.1158/1538-7445.Sabcs19-P2-18-03 |
0.376 |
|
| 2020 |
Cristofanilli M, Dolezal M, Lalezari J, Rui H, Patterson B, Tang C, Adams D, Zhang Q, Kazempour K, Pourhassan N, Rabb N, Dhody K. Abstract CT233: Phase Ib/II study of leronlimab (PRO 140) combined with carboplatin in CCR5+ mTNBC patients Cancer Research. 80. DOI: 10.1158/1538-7445.Am2020-Ct233 |
0.38 |
|
| 2019 |
Flister MJ, Joshi A, Bergom C, Rui H. Mapping Mammary Tumor Traits in the Rat. Methods in Molecular Biology (Clifton, N.J.). 2018: 249-267. PMID 31228161 DOI: 10.1007/978-1-4939-9581-3_12 |
0.377 |
|
| 2019 |
Wright KD, Miller BS, El-Meanawy S, Tsaih SW, Banerjee A, Geurts AM, Sheinin Y, Sun Y, Kalyanaraman B, Rui H, Flister MJ, Sorokin A. The p52 isoform of SHC1 is a key driver of breast cancer initiation. Breast Cancer Research : Bcr. 21: 74. PMID 31202267 DOI: 10.1186/S13058-019-1155-7 |
0.426 |
|
| 2019 |
Plasterer C, Tsaih SW, Peck AR, Chervoneva I, O'Meara C, Sun Y, Lemke A, Murphy D, Smith J, Ran S, Kovatich AJ, Hooke JA, Shriver CD, Hu H, Mitchell EP, ... ... Rui H, et al. Neuronatin is a modifier of estrogen receptor-positive breast cancer incidence and outcome. Breast Cancer Research and Treatment. PMID 31165373 DOI: 10.1007/S10549-019-05307-8 |
0.407 |
|
| 2019 |
Plasterer C, Tsaih SW, Lemke A, Schilling R, Dwinell M, Rau A, Auer P, Rui H, Flister MJ. Identification of a Rat Mammary Tumor Risk Locus That Is Syntenic with the Commonly Amplified 8q12.1 and 8q22.1 Regions in Human Breast Cancer Patients. G3 (Bethesda, Md.). PMID 30914425 DOI: 10.1534/G3.118.200873 |
0.398 |
|
| 2019 |
Ortiz A, Gui J, Zahedi F, Yu P, Cho C, Bhattacharya S, Carbone CJ, Yu Q, Katlinski KV, Katlinskaya YV, Handa S, Haas V, Volk SW, Brice AK, Wals K, ... ... Rui H, et al. An Interferon-Driven Oxysterol-Based Defense against Tumor-Derived Extracellular Vesicles. Cancer Cell. 35: 33-45.e6. PMID 30645975 DOI: 10.1016/J.Ccell.2018.12.001 |
0.318 |
|
| 2019 |
Rau A, Flister M, Rui H, Auer PL. Exploring drivers of gene expression in the Cancer Genome Atlas. Bioinformatics (Oxford, England). 35: 62-68. PMID 30561551 DOI: 10.1093/Bioinformatics/Bty551 |
0.372 |
|
| 2018 |
Gennaro VJ, Stanek TJ, Peck AR, Sun Y, Wang F, Qie S, Knudsen KE, Rui H, Butt T, Diehl JA, McMahon SB. Control of CCND1 ubiquitylation by the catalytic SAGA subunit USP22 is essential for cell cycle progression through G1 in cancer cells. Proceedings of the National Academy of Sciences of the United States of America. PMID 30224477 DOI: 10.1073/Pnas.1807704115 |
0.438 |
|
| 2018 |
Tran TH, Utama FE, Sato T, Peck AR, Langenheim JF, Udhane SS, Sun Y, Liu C, Girondo MA, Kovatich AJ, Hooke JA, Shriver CD, Hu H, Palazzo J, Bibbo M, ... ... Rui H, et al. Loss of nuclear localized Parathyroid Hormone-related Protein in primary breast cancer predicts poor clinical outcome and correlates with suppressed Stat5 signaling. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30097435 DOI: 10.1158/1078-0432.Ccr-17-3280 |
0.435 |
|
| 2018 |
Jiao X, Velasco-Velázquez MA, Wang M, Li Z, Rui H, Peck AR, Korkola JE, Chen X, Xu S, DuHadaway JB, Guerrero-Rodriguez S, Addya S, Sicoli D, Mu Z, Zhang G, et al. CCR5 governs DNA damage and breast cancer stem cell expansion. Cancer Research. PMID 29358169 DOI: 10.1158/0008-5472.Can-17-0915 |
0.446 |
|
| 2018 |
Kumar AP, Kovatich A, Biancotto A, Cheung F, Davidson-Moncada J, Kvecher L, Liu J, Ru Y, Kovatich A, Deyarmin B, Fantacone-Campbell J, Hooke J, Kumar PR, Rui H, Hu H, et al. Abstract P4-09-14: Analysis of breast cancer recurrence using gene set enrichment analysis Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-P4-09-14 |
0.378 |
|
| 2018 |
Chaudhary L, Peck A, Yunguang S, Hu H, Kovatich A, Hooke J, Shriver C, Mitchell E, Chervoneva I, Rui H. Abstract P4-09-06: High levels of Bruton's tyrosine kinase (BTK) protein is associated with favorable outcome in breast cancer Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-P4-09-06 |
0.462 |
|
| 2018 |
Plasterer C, Lemke A, Murphy D, Bergom C, Joshi A, Rui H, Flister MJ. Abstract 408: Evidence of DLL4, NNAT, and SLC35C2 in suppression of breast cancer initiation, growth, and metastasis Cancer Research. 78: 408-408. DOI: 10.1158/1538-7445.Am2018-408 |
0.441 |
|
| 2017 |
Pestell TG, Jiao X, Kumar M, Peck AR, Prisco M, Deng S, Li Z, Ertel A, Casimiro MC, Ju X, Di Rocco A, Di Sante G, Katiyar S, Shupp A, Lisanti MP, ... ... Rui H, et al. Stromal cyclin D1 promotes heterotypic immune signaling and breast cancer growth. Oncotarget. 8: 81754-81775. PMID 29137220 DOI: 10.18632/Oncotarget.19953 |
0.41 |
|
| 2017 |
Ru Y, Liu J, Fantacone-Campbell JL, Zhu K, Kovatich AJ, Hooke JA, Kvecher L, Deyarmin B, Kovatich AW, Cammarata F, Hueman MT, Rui H, Mural RJ, Shriver CD, Hu H. Comparative Survival Analysis of Invasive Breast Cancer Patients Treated by a U.S. Military Medical Center and Matched Patients From the U.S. General Population. Military Medicine. 182: e1851-e1858. PMID 29087852 DOI: 10.7205/Milmed-D-17-00097 |
0.355 |
|
| 2017 |
Morita Y, Zhang R, Leslie M, Adhikari S, Hasan N, Chervoneva I, Rui H, Tanaka T. Pathologic evaluation of tumor-associated macrophage density and vessel inflammation in invasive breast carcinomas. Oncology Letters. 14: 2111-2118. PMID 28789438 DOI: 10.3892/Ol.2017.6466 |
0.353 |
|
| 2017 |
Katlinski KV, Gui J, Katlinskaya YV, Ortiz A, Chakraborty R, Bhattacharya S, Carbone CJ, Beiting DP, Girondo MA, Peck AR, Puré E, Chatterji P, Rustgi AK, Diehl JA, Koumenis C, ... Rui H, et al. Inactivation of Interferon Receptor Promotes the Establishment of Immune Privileged Tumor Microenvironment. Cancer Cell. 31: 194-207. PMID 28196594 DOI: 10.1016/J.Ccell.2017.01.004 |
0.34 |
|
| 2016 |
Morita Y, Kamal M, Kang SA, Zhang R, Lokesh GL, Thiviyanathan V, Hasan N, Woo S, Zhao D, Leslie M, Suh S, Razaq W, Rui H, Gorenstein DG, Volk DE, et al. E-selectin Targeting PEGylated-thioaptamer Prevents Breast Cancer Metastases. Molecular Therapy. Nucleic Acids. 5: e399. PMID 27959340 DOI: 10.1038/Mtna.2016.103 |
0.339 |
|
| 2016 |
Kang SA, Blache CA, Bajana S, Hasan N, Kamal M, Morita Y, Gupta V, Tsolmon B, Suh SK, Gorenstein DG, Razaq W, Rui H, Tanaka T. The effect of soluble E-selectin on tumor progression and metastasis. Bmc Cancer. 16: 331. PMID 27220365 DOI: 10.1186/S12885-016-2366-2 |
0.393 |
|
| 2016 |
Katlinskaya YV, Katlinski KV, Yu Q, Ortiz A, Beiting DP, Brice A, Davar D, Sanders C, Kirkwood JM, Rui H, Xu X, Koumenis C, Diehl JA, Fuchs SY. Suppression of Type I Interferon Signaling Overcomes Oncogene-Induced Senescence and Mediates Melanoma Development and Progression. Cell Reports. PMID 27052162 DOI: 10.1016/J.Celrep.2016.03.006 |
0.343 |
|
| 2016 |
Ru Y, Hu P, Kovatich A, Hooke J, Liu J, Kvecher L, Fantacone-Campbell J, Deyarmin B, Kovatich A, Cammarata F, Rui H, Davidson-Moncada J, Shriver C, Hu H. Abstract P4-09-24: CD163 expression is associated with young age, triple negative subtype, and poor outcome in breast cancer Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P4-09-24 |
0.356 |
|
| 2016 |
Craig J, Kovatich A, Hooke J, Kvecher L, Liu J, Fantacone-Campbell J, Rui H, Shriver C, Hu H. Abstract P4-09-14: PhosphohistoneH3 as a prognostic marker in breast cancer: High expression is associated with younger age, triple negative subtype, and disease specific survival Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P4-09-14 |
0.392 |
|
| 2016 |
Jiao X, Velasco M, Li Z, Xu S, Cristofanilli M, Rui H, Pestell RG. Abstract A19: CCR5 contributes to breast cancer stem cell expansion by enhancing DNA damage repair Cancer Research. 76. DOI: 10.1158/1538-7445.Fbcr15-A19 |
0.389 |
|
| 2015 |
Blanco FF, Jimbo M, Wulfkuhle J, Gallagher I, Deng J, Enyenihi L, Meisner-Kober N, Londin E, Rigoutsos I, Sawicki JA, Risbud MV, Witkiewicz AK, McCue PA, Jiang W, Rui H, et al. The mRNA-binding protein HuR promotes hypoxia-induced chemoresistance through posttranscriptional regulation of the proto-oncogene PIM1 in pancreatic cancer cells. Oncogene. PMID 26387536 DOI: 10.1038/Onc.2015.325 |
0.364 |
|
| 2015 |
Talati PG, Gu L, Ellsworth EM, Girondo MA, Trerotola M, Hoang DT, Leiby B, Dagvadorj A, McCue PA, Lallas CD, Trabulsi EJ, Gomella L, Aplin AE, Languino L, Fatatis A, ... Rui H, et al. Jak2-Stat5a/b Signaling Induces Epithelial-to-Mesenchymal Transition and Stem-Like Cell Properties in Prostate Cancer. The American Journal of Pathology. 185: 2505-22. PMID 26362718 DOI: 10.1016/J.Ajpath.2015.04.026 |
0.365 |
|
| 2015 |
Chen Y, Bekhash A, Kovatich AJ, Hooke JA, Liu J, Kvecher L, Fantacone-Campbell JL, Mitchell EP, Rui H, Mural RJ, Shriver CD, Hu H. Positive Association of Fibroadenomatoid Change with HER2-Negative Invasive Breast Cancer: A Co-Occurrence Study. Plos One. 10: e0129500. PMID 26098961 DOI: 10.1371/Journal.Pone.0129500 |
0.36 |
|
| 2015 |
Goodman CR, Sato T, Peck AR, Girondo MA, Yang N, Liu C, Yanac AF, Kovatich AJ, Hooke JA, Shriver CD, Mitchell EP, Hyslop T, Rui H. Steroid induction of therapy-resistant cytokeratin-5-positive cells in estrogen receptor-positive breast cancer through a BCL6-dependent mechanism. Oncogene. PMID 26096934 DOI: 10.1038/Onc.2015.193 |
0.45 |
|
| 2015 |
Liao Z, Gu L, Vergalli J, Mariani SA, De Dominici M, Lokareddy RK, Dagvadorj A, Purushottamachar P, McCue PA, Trabulsi E, Lallas CD, Gupta S, Ellsworth E, Blackmon S, Ertel A, ... ... Rui H, et al. Structure-Based Screen Identifies a Potent Small Molecule Inhibitor of Stat5a/b with Therapeutic Potential for Prostate Cancer and Chronic Myeloid Leukemia. Molecular Cancer Therapeutics. PMID 26026053 DOI: 10.1158/1535-7163.Mct-14-0883 |
0.388 |
|
| 2015 |
Kang SA, Hasan N, Mann AP, Zheng W, Zhao L, Morris L, Zhu W, Zhao YD, Suh KS, Dooley WC, Volk D, Gorenstein DG, Cristofanilli M, Rui H, Tanaka T. Blocking the adhesion cascade at the premetastatic niche for prevention of breast cancer metastasis. Molecular Therapy : the Journal of the American Society of Gene Therapy. 23: 1044-54. PMID 25815697 DOI: 10.1038/Mt.2015.45 |
0.408 |
|
| 2015 |
Ru Y, Mural RJ, Steeg PS, Rui H, Shriver CD, Hu H. Abstract P6-08-24: Age independently predicts worse disease-specific survival in patients diagnosed with invasive breast cancers at 50 years of age or older but not younger Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P6-08-24 |
0.324 |
|
| 2015 |
Ru Y, Liu J, Campbell JL, Zhu K, Kovatich AJ, Hooke JA, Kvecher L, Deyarmin B, Kovatich AW, Cammarata F, Rui H, Mural RJ, Shriver CD, Hu H. Abstract P3-07-20: Survival comparative analysis of patients with invasive breast cancer treated by a military medical center and matched patients of the US general population Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P3-07-20 |
0.378 |
|
| 2015 |
Rui H, Sato T, Peck A, Girondo MA, Liu C, Kovatich AJ, Hooke JA, Shriver CD, Mitchell E, Hyslop T, Goodman C. Abstract P3-05-10: Glucocorticoid and aldosterone mimic progestin-induction of a therapy-resistant cytokeratin-5 positive cell population in estrogen receptor-positive breast cancer through a Bcl6-dependent mechanism Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P3-05-10 |
0.459 |
|
| 2015 |
Hyslop T, Li X, Duan R, Giuliano M, Giordano A, Orloff M, Rui H, Reuben JM, Cristofanilli M. Abstract 5295: Latent class longitudinal modeling of CTCs in ER+ metastatic breast cancer patients Cancer Research. 75: 5295-5295. DOI: 10.1158/1538-7445.Am2015-5295 |
0.352 |
|
| 2015 |
Check JH, Rosenberg A, DiAntonio A, Rui H, Cohen R, DiAntonio G. Abstract 1281: Serum levels of the immunomodulatory protein, the progesterone induced blocking factor (PIBF) are not higher in women with progesterone (P) receptor (R) positive vs. negative breast cancer Immunology. 75: 1281-1281. DOI: 10.1158/1538-7445.Am2015-1281 |
0.37 |
|
| 2014 |
Wilson C, Lin JE, Li P, Snook AE, Gong J, Sato T, Liu C, Girondo MA, Rui H, Hyslop T, Waldman SA. The paracrine hormone for the GUCY2C tumor suppressor, guanylin, is universally lost in colorectal cancer. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 23: 2328-37. PMID 25304930 DOI: 10.1158/1055-9965.Epi-14-0440 |
0.375 |
|
| 2014 |
Sato T, Tran TH, Peck AR, Girondo MA, Liu C, Goodman CR, Neilson LM, Freydin B, Chervoneva I, Hyslop T, Kovatich AJ, Hooke JA, Shriver CD, Fuchs SY, Rui H. Prolactin suppresses a progestin-induced CK5-positive cell population in luminal breast cancer through inhibition of progestin-driven BCL6 expression. Oncogene. 33: 2215-24. PMID 23708665 DOI: 10.1038/Onc.2013.172 |
0.478 |
|
| 2014 |
Kang S, Hasan N, Suh SK, Rui H, Tanaka T. Abstract 4043: Prevention of breast cancer lung metastasis via the blockade of the adhesion cascade Cancer Research. 74: 4043-4043. DOI: 10.1158/1538-7445.Am2014-4043 |
0.407 |
|
| 2013 |
Li Q, Fu GB, Zheng JT, He J, Niu XB, Chen QD, Yin Y, Qian X, Xu Q, Wang M, Sun AF, Shu Y, Rui H, Liu LZ, Jiang BH. NADPH oxidase subunit p22(phox)-mediated reactive oxygen species contribute to angiogenesis and tumor growth through AKT and ERK1/2 signaling pathways in prostate cancer. Biochimica Et Biophysica Acta. 1833: 3375-85. PMID 24113386 DOI: 10.1016/J.Bbamcr.2013.09.018 |
0.41 |
|
| 2013 |
Yang N, Liu C, Peck AR, Girondo MA, Yanac AF, Tran TH, Utama FE, Tanaka T, Freydin B, Chervoneva I, Hyslop T, Kovatich AJ, Hooke JA, Shriver CD, Rui H. Prolactin-Stat5 signaling in breast cancer is potently disrupted by acidosis within the tumor microenvironment. Breast Cancer Research : Bcr. 15: R73. PMID 24004716 DOI: 10.1186/Bcr3467 |
0.474 |
|
| 2013 |
Chen K, Wu K, Gormley M, Ertel A, Wang J, Zhang W, Zhou J, Disante G, Li Z, Rui H, Quong AA, McMahon SB, Deng H, Lisanti MP, Wang C, et al. Acetylation of the cell-fate factor dachshund determines p53 binding and signaling modules in breast cancer. Oncotarget. 4: 923-35. PMID 23798621 DOI: 10.18632/Oncotarget.1094 |
0.425 |
|
| 2013 |
Sato T, Tran TH, Peck AR, Liu C, Ertel A, Lin J, Neilson LM, Rui H. Global profiling of prolactin-modulated transcripts in breast cancer in vivo. Molecular Cancer. 12: 59. PMID 23758962 DOI: 10.1186/1476-4598-12-59 |
0.457 |
|
| 2013 |
Haddad BR, Gu L, Mirtti T, Dagvadorj A, Vogiatzi P, Hoang DT, Bajaj R, Leiby B, Ellsworth E, Blackmon S, Ruiz C, Curtis M, Fortina P, Ertel A, Liu C, ... Rui H, et al. STAT5A/B gene locus undergoes amplification during human prostate cancer progression. The American Journal of Pathology. 182: 2264-75. PMID 23660011 DOI: 10.1016/J.Ajpath.2013.02.044 |
0.359 |
|
| 2013 |
Chen K, Wu K, Cai S, Zhang W, Zhou J, Wang J, Ertel A, Li Z, Rui H, Quong A, Lisanti MP, Tozeren A, Tanes C, Addya S, Gormley M, et al. Dachshund binds p53 to block the growth of lung adenocarcinoma cells. Cancer Research. 73: 3262-74. PMID 23492369 DOI: 10.1158/0008-5472.Can-12-3191 |
0.341 |
|
| 2013 |
Lin WC, Rajbhandari N, Liu C, Sakamoto K, Zhang Q, Triplett AA, Batra SK, Opavsky R, Felsher DW, DiMaio DJ, Hollingsworth MA, Morris JP, Hebrok M, Witkiewicz AK, Brody JR, ... Rui H, et al. Dormant cancer cells contribute to residual disease in a model of reversible pancreatic cancer. Cancer Research. 73: 1821-30. PMID 23467612 DOI: 10.1158/0008-5472.Can-12-2067 |
0.396 |
|
| 2013 |
Hyslop T, Michael Y, Avery T, Rui H. Population and target considerations for triple-negative breast cancer clinical trials. Biomarkers in Medicine. 7: 11-21. PMID 23387481 DOI: 10.2217/Bmm.12.114 |
0.344 |
|
| 2013 |
Avery TP, Berger AC, Kovatich AJ, Rui H, Hyslop T, Mitchell EP. An adaptive randomized phase II trial to determine pathologic complete response with the addition of carboplatin with and without ABT-888 to standard chemotherapy in the neoadjuvant treatment of triple-negative breast cancer. Journal of Clinical Oncology. 31: TPS1135-TPS1135. DOI: 10.1200/Jco.2013.31.15_Suppl.Tps1135 |
0.302 |
|
| 2013 |
Blache CA, Hasan N, Park J, Suh S, Gorenstein DG, Rui H, Tanaka T. Abstract 4992: A novel role of soluble E-selectin as a chemoatractant to human leukocytes through the PI3kinase signaling pathway in breast cancer. Cancer Research. 73: 4992-4992. DOI: 10.1158/1538-7445.Am2013-4992 |
0.452 |
|
| 2013 |
Yoshida M, Selvan S, McCue PA, DeAngelis T, Fujii A, Rui H, Baserga R, Mastrangelo M, Sato T. Abstract 2815: Expression of insulin-like growth factor-1 receptor in metastatic uveal melanoma and implications for potential autocrine and paracrine tumor cell growth. Cancer Research. 73: 2815-2815. DOI: 10.1158/1538-7445.Am2013-2815 |
0.326 |
|
| 2013 |
Cunningham I, Shiomi T, D'Armiento JM, Rui H, Cordon-Cardo C, Hamele-Bena D. Abstract 1096: Hiding from chemo: Leukemic cells forming tumors to survive. Cancer Research. 73: 1096-1096. DOI: 10.1158/1538-7445.Am2013-1096 |
0.417 |
|
| 2013 |
Pestell R, Chen K, Wu K, Gormley M, Ertel A, Zhang W, Zhou J, DiSante G, Li Z, Rui H, Quong A, McMahon S, Deng H, Lisanti M, Wang C. Abstract P5-11-04: Post-translational modification of the cell-fate factor Dachshund determines p53 binding and signaling modules in breast cancer Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-P5-11-04 |
0.456 |
|
| 2013 |
Rui H, Zhang J, Yanac A, Utama F, Girondo M, Peck A, Rosenberg A, Yang N. Abstract P5-04-05: Preclinical modeling of luminal breast cancer: Recapitulating progression to lethal and tamoxifen-resistant lung metastases in novel patient-derived xenotransplant models in prolactin-humanized mice Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-P5-04-05 |
0.422 |
|
| 2013 |
Chen Y, Kovatich A, Fantacone-Campbell J, Hooke J, Kvecher L, Kovatich A, Gallagher C, Hueman M, Hyslop T, Mural R, Shriver C, Rui H, Hu H. Abstract P4-06-09: HER2+ and HER2- luminal B subtypes have similar overall survival and histologic grade distributions Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-P4-06-09 |
0.341 |
|
| 2013 |
Kovatich A, Chen Y, Fantacone-Campbell J, Wareham J, Tafra L, Kvecher L, Hyslop T, Hooke J, Rui H, Shriver C, Mural R, Hu H. Abstract P4-06-03: Assays on core biopsies and surgically resected tumors may result in different subtyping of the invasive breast cancer from the same patient Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-P4-06-03 |
0.354 |
|
| 2013 |
Girondo M, Peck A, Freydin B, Chervoneva I, Hyslop T, Kovatich A, Hooke J, Shriver C, Mitchell E, Rui H. Abstract P1-08-20: Increased risk of hormone therapy failure in breast cancers expressing low phospho-Stat5: Validation of quantitative immunofluorescence assay parameters Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-P1-08-20 |
0.448 |
|
| 2013 |
Peck A, Yang N, Yanac A, Utama F, Jasinski J, Rosenberg A, Tanaka T, Rui H. Abstract P1-06-10: Characterization of novel activated human mammary fibroblast lines and their protumorigenic effect on human breast cancer xenotransplants in mice Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-P1-06-10 |
0.464 |
|
| 2012 |
Peck AR, Witkiewicz AK, Liu C, Klimowicz AC, Stringer GA, Pequignot E, Freydin B, Yang N, Ertel A, Tran TH, Girondo MA, Rosenberg AL, Hooke JA, Kovatich AJ, Shriver CD, ... ... Rui H, et al. Low levels of Stat5a protein in breast cancer are associated with tumor progression and unfavorable clinical outcomes. Breast Cancer Research : Bcr. 14: R130. PMID 23036105 DOI: 10.1186/Bcr3328 |
0.437 |
|
| 2012 |
Huangfu WC, Qian J, Liu C, Liu J, Lokshin AE, Baker DP, Rui H, Fuchs SY. Inflammatory signaling compromises cell responses to interferon alpha. Oncogene. 31: 161-72. PMID 21666722 DOI: 10.1038/Onc.2011.221 |
0.336 |
|
| 2012 |
Lin W, Rajbhandari N, Liu C, Sakamoto K, Batra S, Opavsky R, Felsher D, Hollingsworth M, Hebrok M, Rui H, Wagner K. Abstract LB-429: Dormant cancer cells contribute to residual disease in a mouse model for reversible pancreatic cancer Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Lb-429 |
0.395 |
|
| 2012 |
Chen K, Wu K, Zhang W, Zhou J, Stanek T, Li Z, Wang C, Shirley LA, Rui H, Mcmahon S, Pestell RG. Abstract LB-144: A p53-dependent G2/M checkpoint governed by the cell-fate factor dachshund in non-small cell lung cancer Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Lb-144 |
0.389 |
|
| 2012 |
Rui H, Utama F, Yanac A, Xia G, Peck A, Liu C, Rosenberg A, Wagner K, Yang N. Abstract S1-8: Prolactin-humanized mice: an improved animal recipient for therapy response-testing of patient-derived breast cancer xenotransplants Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-S1-8 |
0.367 |
|
| 2012 |
Chen Y, Bekhash A, Kovatich A, Hooke J, Kvecher L, Mitchell E, Rui H, Mural R, Shriver C, Hu H. Abstract P5-01-07: Fibroadenomatoid changes are more prevalent in middle-aged women and have a positive association with invasive breast cancer Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-P5-01-07 |
0.329 |
|
| 2012 |
Kovatich A, Luo C, Chen Y, Hooke J, Kvecher L, Rui H, Shriver C, Mural R, Hu H. Abstract P2-05-21: Molecular subtypes of invasive breast cancers show differential expression of the proliferation marker Aurora Kinase A (AURKA) Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-P2-05-21 |
0.426 |
|
| 2011 |
Yang N, Utama FE, Yanac AF, Liu C, Rosenberg AL, Rui H. Xenotransplantation of surgical specimens of human breast cancer directly into genetically engineered prolactin-humanized immunodeficient mice. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 76. PMID 27958105 DOI: 10.1200/Jco.2011.29.27_Suppl.76 |
0.44 |
|
| 2011 |
Zhang Q, Sakamoto K, Liu C, Triplett AA, Lin WC, Rui H, Wagner KU. Cyclin D3 compensates for the loss of cyclin D1 during ErbB2-induced mammary tumor initiation and progression. Cancer Research. 71: 7513-24. PMID 22037875 DOI: 10.1158/0008-5472.Can-11-1783 |
0.398 |
|
| 2011 |
Sato T, Neilson LM, Peck AR, Liu C, Tran TH, Witkiewicz A, Hyslop T, Nevalainen MT, Sauter G, Rui H. Signal transducer and activator of transcription-3 and breast cancer prognosis. American Journal of Cancer Research. 1: 347-55. PMID 21776434 |
0.348 |
|
| 2011 |
Peck AR, Witkiewicz AK, Liu C, Stringer GA, Klimowicz AC, Pequignot E, Freydin B, Tran TH, Yang N, Rosenberg AL, Hooke JA, Kovatich AJ, Nevalainen MT, Shriver CD, Hyslop T, ... ... Rui H, et al. Loss of nuclear localized and tyrosine phosphorylated Stat5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2448-58. PMID 21576635 DOI: 10.1200/Jco.2010.30.3552 |
0.393 |
|
| 2011 |
Michal AM, Peck AR, Tran TH, Liu C, Rimm DL, Rui H, Benovic JL. Differential expression of arrestins is a predictor of breast cancer progression and survival. Breast Cancer Research and Treatment. 130: 791-807. PMID 21318602 DOI: 10.1007/S10549-011-1374-9 |
0.45 |
|
| 2011 |
Arendt LM, Rugowski DE, Grafwallner-Huseth TA, Garcia-Barchino MJ, Rui H, Schuler LA. Prolactin-induced mouse mammary carcinomas model estrogen resistant luminal breast cancer. Breast Cancer Research : Bcr. 13: R11. PMID 21276249 DOI: 10.1186/Bcr2819 |
0.394 |
|
| 2011 |
Behling KC, Tang A, Freydin B, Chervoneva I, Kadakia S, Schwartz GF, Rui H, Witkiewicz AK. Increased SIAH expression predicts ductal carcinoma in situ (DCIS) progression to invasive carcinoma. Breast Cancer Research and Treatment. 129: 717-24. PMID 21088888 DOI: 10.1007/S10549-010-1254-8 |
0.418 |
|
| 2011 |
Sato T, Tran T, Neilson L, Rui H. Abstract 3097: Global transcript profiling for prolactin-stat5 dependent target genes in breast cancer Cellular and Molecular Biology. 71: 3097-3097. DOI: 10.1158/1538-7445.Am2011-3097 |
0.414 |
|
| 2011 |
Peck AR, Witkiewicz AK, Liu C, Stringer GA, Klimowicz AC, Pequignot E, Freydin B, Tran TH, Yang N, Rosenberg AL, Hooke JA, Kovatich AJ, Nevalainen MT, Shriver CD, Hyslop T, ... ... Rui H, et al. Abstract 2277: Loss of nuclear localized and tyrosine phosphorylated Stat5: A predictor of poor clinical outcome and increased risk of antiestrogen therapy failure in breast cancer Cancer Research. 71: 2277-2277. DOI: 10.1158/1538-7445.Am2011-2277 |
0.407 |
|
| 2011 |
Eberhardt J, Hyslop T, Mitchell E, Hu H, Rui H. P5-14-12: Bayesian Belief Network Mortality Analysis of a Breast Cancer Registry Data Set. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-P5-14-12 |
0.306 |
|
| 2011 |
Peck A, Witkiewicz A, Liu C, Klimowicz A, Stringer G, Pequignot E, Freydin B, Yang N, Tran T, Rosenberg A, Hooke J, Kovatich A, Shriver C, Rimm D, Magliocco A, ... ... Rui H, et al. P1-06-24: Nuclear Localization of Stat5a Predicts Response to Antiestrogen Therapy and Prognosis of Clinical Breast Cancer Outcome. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-P1-06-24 |
0.414 |
|
| 2010 |
HuangFu WC, Qian J, Liu C, Rui H, Fuchs SY. Melanoma cell-secreted soluble factor that stimulates ubiquitination and degradation of the interferon alpha receptor and attenuates its signaling. Pigment Cell & Melanoma Research. 23: 838-40. PMID 21644263 DOI: 10.1111/J.1755-148X.2010.00770.X |
0.352 |
|
| 2010 |
Varghese B, Swaminathan G, Plotnikov A, Tzimas C, Yang N, Rui H, Fuchs SY. Prolactin inhibits activity of pyruvate kinase M2 to stimulate cell proliferation. Molecular Endocrinology (Baltimore, Md.). 24: 2356-65. PMID 20962042 DOI: 10.1210/Me.2010-0219 |
0.394 |
|
| 2010 |
Johnson KJ, Peck AR, Liu C, Tran TH, Utama FE, Sjolund AB, Schaber JD, Witkiewicz AK, Rui H. PTP1B suppresses prolactin activation of Stat5 in breast cancer cells. The American Journal of Pathology. 177: 2971-83. PMID 20952588 DOI: 10.2353/Ajpath.2010.090399 |
0.469 |
|
| 2010 |
Ertel A, Dean JL, Rui H, Liu C, Witkiewicz AK, Knudsen KE, Knudsen ES. RB-pathway disruption in breast cancer: differential association with disease subtypes, disease-specific prognosis and therapeutic response. Cell Cycle (Georgetown, Tex.). 9: 4153-63. PMID 20948315 DOI: 10.4161/Cc.9.20.13454 |
0.412 |
|
| 2010 |
Dagvadorj A, Tan SH, Liao Z, Xie J, Nurmi M, Alanen K, Rui H, Mirtti T, Nevalainen MT. N-terminal truncation of Stat5a/b circumvents PIAS3-mediated transcriptional inhibition of Stat5 in prostate cancer cells. The International Journal of Biochemistry & Cell Biology. 42: 2037-46. PMID 20854925 DOI: 10.1016/J.Biocel.2010.09.008 |
0.384 |
|
| 2010 |
Tran TH, Utama FE, Lin J, Yang N, Sjolund AB, Ryder A, Johnson KJ, Neilson LM, Liu C, Brill KL, Rosenberg AL, Witkiewicz AK, Rui H. Prolactin inhibits BCL6 expression in breast cancer through a Stat5a-dependent mechanism. Cancer Research. 70: 1711-21. PMID 20124477 DOI: 10.1158/0008-5472.Can-09-2314 |
0.477 |
|
| 2010 |
Hyslop T, Foley KA, Rui H, Mitchell E. Abstract A102: The role of socioeconomic status, pathology and genetic biomarkers in explaining racial disparities in breast cancer survival Cancer Epidemiology, Biomarkers & Prevention. 19. DOI: 10.1158/1055-9965.Disp-10-A102 |
0.402 |
|
| 2009 |
Nagy ZS, LeBaron MJ, Ross JA, Mitra A, Rui H, Kirken RA. STAT5 regulation of BCL10 parallels constitutive NFkappaB activation in lymphoid tumor cells. Molecular Cancer. 8: 67. PMID 19709433 DOI: 10.1186/1476-4598-8-67 |
0.678 |
|
| 2009 |
Comstock CE, Augello MA, Benito RP, Karch J, Tran TH, Utama FE, Tindall EA, Wang Y, Burd CJ, Groh EM, Hoang HN, Giles GG, Severi G, Hayes VM, Henderson BE, ... ... Rui H, et al. Cyclin D1 splice variants: polymorphism, risk, and isoform-specific regulation in prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 5338-49. PMID 19706803 DOI: 10.1158/1078-0432.Ccr-08-2865 |
0.324 |
|
| 2009 |
Arendt LM, Evans LC, Rugowski DE, Garcia-Barchino MJ, Rui H, Schuler LA. Ovarian hormones are not required for PRL-induced mammary tumorigenesis, but estrogen enhances neoplastic processes. The Journal of Endocrinology. 203: 99-110. PMID 19635758 DOI: 10.1677/Joe-09-0221 |
0.421 |
|
| 2009 |
Popov VM, Zhou J, Shirley LA, Quong J, Yeow WS, Wright JA, Wu K, Rui H, Vadlamudi RK, Jiang J, Kumar R, Wang C, Pestell RG. The cell fate determination factor DACH1 is expressed in estrogen receptor-alpha-positive breast cancer and represses estrogen receptor-alpha signaling. Cancer Research. 69: 5752-60. PMID 19605405 DOI: 10.1158/0008-5472.Can-08-3992 |
0.457 |
|
| 2009 |
Witkiewicz AK, Dasgupta A, Nguyen KH, Liu C, Kovatich AJ, Schwartz GF, Pestell RG, Sotgia F, Rui H, Lisanti MP. Stromal caveolin-1 levels predict early DCIS progression to invasive breast cancer. Cancer Biology & Therapy. 8: 1071-9. PMID 19502809 DOI: 10.4161/Cbt.8.11.8874 |
0.392 |
|
| 2009 |
Mercier I, Casimiro MC, Zhou J, Wang C, Plymire C, Bryant KG, Daumer KM, Sotgia F, Bonuccelli G, Witkiewicz AK, Lin J, Tran TH, Milliman J, Frank PG, Jasmin JF, ... Rui H, et al. Genetic ablation of caveolin-1 drives estrogen-hypersensitivity and the development of DCIS-like mammary lesions. The American Journal of Pathology. 174: 1172-90. PMID 19342371 DOI: 10.2353/Ajpath.2009.080882 |
0.414 |
|
| 2009 |
Millar EK, Dean JL, McNeil CM, O'Toole SA, Henshall SM, Tran T, Lin J, Quong A, Comstock CE, Witkiewicz A, Musgrove EA, Rui H, Lemarchand L, Setiawan VW, Haiman CA, et al. Cyclin D1b protein expression in breast cancer is independent of cyclin D1a and associated with poor disease outcome. Oncogene. 28: 1812-20. PMID 19287456 DOI: 10.1038/Onc.2009.13 |
0.422 |
|
| 2009 |
Plotnikov A, Varghese B, Tran TH, Liu C, Rui H, Fuchs SY. Impaired turnover of prolactin receptor contributes to transformation of human breast cells. Cancer Research. 69: 3165-72. PMID 19276348 DOI: 10.1158/0008-5472.Can-08-4033 |
0.473 |
|
| 2009 |
Sotgia F, Casimiro MC, Bonuccelli G, Liu M, Whitaker-Menezes D, Er O, Daumer KM, Mercier I, Witkiewicz AK, Minetti C, Capozza F, Gormley M, Quong AA, Rui H, Frank PG, et al. Loss of caveolin-3 induces a lactogenic microenvironment that is protective against mammary tumor formation. The American Journal of Pathology. 174: 613-29. PMID 19164602 DOI: 10.2353/Ajpath.2009.080653 |
0.411 |
|
| 2009 |
Utama FE, Tran TH, Ryder A, LeBaron MJ, Parlow AF, Rui H. Insensitivity of human prolactin receptors to nonhuman prolactins: relevance for experimental modeling of prolactin receptor-expressing human cells. Endocrinology. 150: 1782-90. PMID 19022890 DOI: 10.1210/En.2008-1057 |
0.694 |
|
| 2008 |
Wang Y, Dean JL, Millar EK, Tran TH, McNeil CM, Burd CJ, Henshall SM, Utama FE, Witkiewicz A, Rui H, Sutherland RL, Knudsen KE, Knudsen ES. Cyclin D1b is aberrantly regulated in response to therapeutic challenge and promotes resistance to estrogen antagonists. Cancer Research. 68: 5628-38. PMID 18632615 DOI: 10.1158/0008-5472.Can-07-3170 |
0.431 |
|
| 2008 |
Plotnikov A, Li Y, Tran TH, Tang W, Palazzo JP, Rui H, Fuchs SY. Oncogene-mediated inhibition of glycogen synthase kinase 3 beta impairs degradation of prolactin receptor. Cancer Research. 68: 1354-61. PMID 18316598 DOI: 10.1158/0008-5472.Can-07-6094 |
0.43 |
|
| 2008 |
Wagner KU, Rui H. Jak2/Stat5 signaling in mammogenesis, breast cancer initiation and progression. Journal of Mammary Gland Biology and Neoplasia. 13: 93-103. PMID 18228120 DOI: 10.1007/S10911-008-9062-Z |
0.476 |
|
| 2008 |
Witkiewicz A, Ryder A, Neilson LM, Utama FE, Tran TH, Hyslop T, Rui H. Transcription factors Stat5a and Stat5b: Favorable prognostic markers in breast cancer Journal of Clinical Oncology. 26: 22071-22071. DOI: 10.1200/Jco.2008.26.15_Suppl.22071 |
0.425 |
|
| 2008 |
Nagy ZS, LeBaron MJ, Rui H, Kirken RA. 184 The NFκB regulator Bcl10 is a novel Stat5 target gene Cytokine. 43: 283. DOI: 10.1016/J.Cyto.2008.07.246 |
0.632 |
|
| 2007 |
Neilson LM, Zhu J, Xie J, Malabarba MG, Sakamoto K, Wagner KU, Kirken RA, Rui H. Coactivation of janus tyrosine kinase (Jak)1 positively modulates prolactin-Jak2 signaling in breast cancer: recruitment of ERK and signal transducer and activator of transcription (Stat)3 and enhancement of Akt and Stat5a/b pathways. Molecular Endocrinology (Baltimore, Md.). 21: 2218-32. PMID 17550976 DOI: 10.1210/Me.2007-0173 |
0.442 |
|
| 2007 |
Dalmizrak O, Wu A, Chen J, Sun H, Utama FE, Zambelli D, Tran TH, Rui H, Baserga R. Insulin receptor substrate-1 regulates the transformed phenotype of BT-20 human mammary cancer cells. Cancer Research. 67: 2124-30. PMID 17332342 DOI: 10.1158/0008-5472.Can-06-3954 |
0.417 |
|
| 2007 |
LeBaron MJ, Ahonen TJ, Nevalainen MT, Rui H. In vivo response-based identification of direct hormone target cell populations using high-density tissue arrays. Endocrinology. 148: 989-1008. PMID 17138649 DOI: 10.1210/En.2006-1219 |
0.674 |
|
| 2007 |
Morris GJ, Topham AK, Guiles F, McCue P, Schwartz GF, Park PK, Rosenberg AL, Brill K, Rui H, Mitchell EP. Biomarker analysis by breast cancer phenotype in African-American versus Caucasian patients: Correlates with survival Journal of Clinical Oncology. 25: 10551-10551. DOI: 10.1200/Jco.2007.25.18_Suppl.10551 |
0.363 |
|
| 2006 |
Sotgia F, Rui H, Bonuccelli G, Mercier I, Pestell RG, Lisanti MP. Caveolin-1, mammary stem cells, and estrogen-dependent breast cancers. Cancer Research. 66: 10647-51. PMID 17108100 DOI: 10.1158/0008-5472.Can-06-2805 |
0.455 |
|
| 2006 |
Williams TM, Sotgia F, Lee H, Hassan G, Di Vizio D, Bonuccelli G, Capozza F, Mercier I, Rui H, Pestell RG, Lisanti MP. Stromal and epithelial caveolin-1 both confer a protective effect against mammary hyperplasia and tumorigenesis: Caveolin-1 antagonizes cyclin D1 function in mammary epithelial cells. The American Journal of Pathology. 169: 1784-801. PMID 17071600 DOI: 10.2353/Ajpath.2006.060590 |
0.42 |
|
| 2006 |
Nagy ZS, Rui H, Stepkowski SM, Karras J, Kirken RA. A preferential role for STAT5, not constitutively active STAT3, in promoting survival of a human lymphoid tumor. Journal of Immunology (Baltimore, Md. : 1950). 177: 5032-40. PMID 17015686 DOI: 10.4049/Jimmunol.177.8.5032 |
0.386 |
|
| 2006 |
Utama FE, LeBaron MJ, Neilson LM, Sultan AS, Parlow AF, Wagner KU, Rui H. Human prolactin receptors are insensitive to mouse prolactin: implications for xenotransplant modeling of human breast cancer in mice. The Journal of Endocrinology. 188: 589-601. PMID 16522738 DOI: 10.1677/joe.1.06560 |
0.688 |
|
| 2005 |
Rui H, LeBaron MJ. Creating tissue microarrays by cutting-edge matrix assembly. Expert Review of Medical Devices. 2: 673-80. PMID 16293094 DOI: 10.1586/17434440.2.6.673 |
0.612 |
|
| 2005 |
LeBaron MJ, Crismon HR, Utama FE, Neilson LM, Sultan AS, Johnson KJ, Andersson EC, Rui H. Ultrahigh density microarrays of solid samples. Nature Methods. 2: 511-3. PMID 15973421 DOI: 10.1038/Nmeth772 |
0.604 |
|
| 2005 |
LeBaron MJ, Xie J, Rui H. Evaluation of genome-wide chromatin library of Stat5 binding sites in human breast cancer. Molecular Cancer. 4: 6. PMID 15686596 DOI: 10.1186/1476-4598-4-6 |
0.704 |
|
| 2005 |
Sultan AS, Xie J, LeBaron MJ, Ealley EL, Nevalainen MT, Rui H. Stat5 promotes homotypic adhesion and inhibits invasive characteristics of human breast cancer cells. Oncogene. 24: 746-60. PMID 15592524 DOI: 10.1038/Sj.Onc.1208203 |
0.723 |
|
| 2005 |
Sakamoto K, Krempler A, Triplett A, Zhu J, Rui H, Wagner K. Essential functions of the Janus kinase 2 (Jak2) during mammary gland development and tumorigenesis Breast Cancer Research. 7: 1-1. DOI: 10.1186/Bcr1125 |
0.462 |
|
| 2004 |
Krempler A, Qi Y, Triplett AA, Zhu J, Rui H, Wagner KU. Generation of a conditional knockout allele for the Janus kinase 2 (Jak2) gene in mice. Genesis (New York, N.Y. : 2000). 40: 52-7. PMID 15354294 DOI: 10.1002/Gene.20063 |
0.326 |
|
| 2004 |
Wagner KU, Krempler A, Triplett AA, Qi Y, George NM, Zhu J, Rui H. Impaired alveologenesis and maintenance of secretory mammary epithelial cells in Jak2 conditional knockout mice Molecular and Cellular Biology. 24: 5510-5520. PMID 15169911 DOI: 10.1128/Mcb.24.12.5510-5520.2004 |
0.382 |
|
| 2004 |
Nevalainen MT, Xie J, Torhorst J, Bubendorf L, Haas P, Kononen J, Sauter G, Rui H. Signal transducer and activator of transcription-5 activation and breast cancer prognosis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 2053-60. PMID 15169792 DOI: 10.1200/Jco.2004.11.046 |
0.433 |
|
| 2003 |
Ahonen TJ, Xie J, LeBaron MJ, Zhu J, Nurmi M, Alanen K, Rui H, Nevalainen MT. Inhibition of transcription factor Stat5 induces cell death of human prostate cancer cells. The Journal of Biological Chemistry. 278: 27287-92. PMID 12719422 DOI: 10.1074/Jbc.M304307200 |
0.692 |
|
| 2003 |
Benitah SA, Valerón PF, Rui H, Lacal JC. STAT5a activation mediates the epithelial to mesenchymal transition induced by oncogenic RhoA. Molecular Biology of the Cell. 14: 40-53. PMID 12529425 DOI: 10.1091/Mbc.E02-08-0454 |
0.35 |
|
| 2002 |
Nagy ZS, Wang Y, Erwin-Cohen RA, Aradi J, Monia B, Wang LH, Stepkowski SM, Rui H, Kirken RA. Interleukin-2 family cytokines stimulate phosphorylation of the Pro-Ser-Pro motif of Stat5 transcription factors in human T cells: resistance to suppression of multiple serine kinase pathways. Journal of Leukocyte Biology. 72: 819-28. PMID 12377952 DOI: 10.1189/Jlb.72.4.819 |
0.342 |
|
| 2002 |
Boer AK, Drayer AL, Rui H, Vellenga E. Prostaglandin-E2 enhances EPO-mediated STAT5 transcriptional activity by serine phosphorylation of CREB. Blood. 100: 467-73. PMID 12091337 DOI: 10.1182/Blood.V100.2.467 |
0.356 |
|
| 2002 |
Nevalainen MT, Xie J, Bubendorf L, Wagner KU, Rui H. Basal activation of transcription factor signal transducer and activator of transcription (Stat5) in nonpregnant mouse and human breast epithelium. Molecular Endocrinology (Baltimore, Md.). 16: 1108-24. PMID 11981045 DOI: 10.1210/Mend.16.5.0839 |
0.44 |
|
| 2002 |
Xie J, LeBaron MJ, Nevalainen MT, Rui H. Role of tyrosine kinase Jak2 in prolactin-induced differentiation and growth of mammary epithelial cells. The Journal of Biological Chemistry. 277: 14020-30. PMID 11821424 DOI: 10.1074/Jbc.M112399200 |
0.711 |
|
| 2002 |
Ahonen TJ, Härkönen PL, Rui H, Nevalainen MT. PRL signal transduction in the epithelial compartment of rat prostate maintained as long-term organ cultures in vitro. Endocrinology. 143: 228-38. PMID 11751614 DOI: 10.1210/Endo.143.1.8576 |
0.343 |
|
| 2001 |
Park SH, Yamashita H, Rui H, Waxman DJ. Serine phosphorylation of GH-activated signal transducer and activator of transcription 5a (STAT5a) and STAT5b: Impact on STAT5 transcriptional activity Molecular Endocrinology. 15: 2157-2171. PMID 11731617 DOI: 10.1210/Mend.15.12.0746 |
0.348 |
|
| 2001 |
Yamashita H, Nevalainen MT, Xu J, LeBaron MJ, Wagner KU, Erwin RA, Harmon JM, Hennighausen L, Kirken RA, Rui H. Role of serine phosphorylation of Stat5a in prolactin-stimulated β-casein gene expression Molecular and Cellular Endocrinology. 183: 151-163. PMID 11604235 DOI: 10.1016/S0303-7207(01)00546-9 |
0.668 |
|
| 2000 |
Kirken RA, Erwin RA, Wang L, Wang Y, Rui H, Farrar WL. Functional uncoupling of the Janus kinase 3-Stat5 pathway in malignant growth of human T cell leukemia virus type 1-transformed human T cells. Journal of Immunology (Baltimore, Md. : 1950). 165: 5097-104. PMID 11046040 DOI: 10.4049/Jimmunol.165.9.5097 |
0.333 |
|
| 2000 |
Nevalainen MT, Ahonen TJ, Yamashita H, Chandrashekar V, Bartke A, Grimley PM, Robinson GW, Hennighausen L, Rui H. Epithelial defect in prostates of Stat5a-null mice. Laboratory Investigation; a Journal of Technical Methods and Pathology. 80: 993-1006. PMID 10908145 DOI: 10.1038/Labinvest.3780105 |
0.309 |
|
| 2000 |
Grimley PM, Dong F, Rui H. Stat5a and Stat5b: fraternal twins of signal transduction and transcriptional activation. Cytokine & Growth Factor Reviews. 10: 131-57. PMID 10743504 DOI: 10.1016/S1359-6101(99)00011-8 |
0.367 |
|
| 1999 |
Ahonen TJ, Ha Rko Nen PL, Laine J, Rui H, Martikainen PM, Nevalainen MT. Prolactin Is a Survival Factor for Androgen-Deprived Rat Dorsal and Lateral Prostate Epithelium in Organ Culture1. Endocrinology. 140: 5412-5421. PMID 28200565 DOI: 10.1210/Endo.140.11.7090 |
0.307 |
|
| 1999 |
Yamashita H, Xu J, Erwin RA, Larner AC, Rui H. A lymphoma growth inhibitor blocks some but not all prolactin-stimulated signaling pathways. The Journal of Biological Chemistry. 274: 14699-705. PMID 10329665 DOI: 10.1074/Jbc.274.21.14699 |
0.351 |
|
| 1998 |
Yamashita H, Xu J, Erwin RA, Farrar WL, Kirken RA, Rui H. Differential control of the phosphorylation state of proline-juxtaposed serine residues Ser725 of Stat5a and Ser730 of Stat5b in prolactin-sensitive cells. The Journal of Biological Chemistry. 273: 30218-24. PMID 9804779 DOI: 10.1074/Jbc.273.46.30218 |
0.323 |
|
| 1998 |
Grimley PM, Fang H, Rui H, Petricoin EF, Ray S, Dong F, Fields KH, Hu R, Zoon KC, Audet S, Beeler J. Prolonged STAT1 activation related to the growth arrest of malignant lymphoma cells by interferon-α Blood. 91: 3017-3027. PMID 9531615 DOI: 10.1182/Blood.V91.8.3017.3017_3017_3027 |
0.352 |
|
| 1998 |
Rui H, Xu J, Mehta S, Fang H, Williams J, Dong F, Grimley PM. Activation of the Jak2-Stat5 signaling pathway in Nb2 lymphoma cells by an anti-apoptotic agent, aurintricarboxylic acid Journal of Biological Chemistry. 273: 28-32. PMID 9417042 DOI: 10.1074/Jbc.273.1.28 |
0.386 |
|
| 1997 |
Kirken RA, Malabarba MG, Xu J, Liu X, Farrar WL, Hennighausen L, Larner AC, Grimley PM, Rui H. Prolactin stimulates serine/tyrosine phosphorylation and formation of heterocomplexes of multiple Stat5 isoforms in Nb2 lymphocytes. The Journal of Biological Chemistry. 272: 14098-103. PMID 9162035 DOI: 10.1074/Jbc.272.22.14098 |
0.376 |
|
| 1997 |
DaSilva L, Rui H, Erwin RA, Howard OM, Kirken RA, Malabarba MG, Hackett RH, Larner AC, Farrar WL. Prolactin recruits STAT1, STAT3 and STAT5 independent of conserved receptor tyrosines TYR402, TYR479, TYR515 and TYR580. Molecular and Cellular Endocrinology. 117: 131-40. PMID 8737372 DOI: 10.1016/0303-7207(95)03738-1 |
0.363 |
|
| 1995 |
Erwin RA, Kirken RA, Malabarba MG, Farrar WL, Rui H. Prolactin activates Ras via signaling proteins SHC, growth factor receptor bound 2, and son of sevenless. Endocrinology. 136: 3512-8. PMID 7628388 DOI: 10.1210/Endo.136.8.7628388 |
0.351 |
|
| 1994 |
Rui H, Lebrun JJ, Kirken RA, Kelly PA, Farrar WL. JAK2 activation and cell proliferation induced by antibody-mediated prolactin receptor dimerization. Endocrinology. 135: 1299-306. PMID 7925093 DOI: 10.1210/Endo.135.4.7925093 |
0.314 |
|
| 1994 |
Kirken RA, Rui H, Howard OM, Farrar WL. Involvement of JAK-family tyrosine kinases in hematopoietin receptor signal transduction. Progress in Growth Factor Research. 5: 195-211. PMID 7919224 DOI: 10.1016/0955-2235(94)90005-1 |
0.303 |
|
| 1993 |
Evans GA, Rui H, Farrar WL. 3 - Identification of Intracellular Mediators of the Actions of Cytokines: Identifying Proteins Involved in Kinase Signaling Pathways Methods in Neurosciences. 16: 49-66. DOI: 10.1016/B978-0-12-185281-8.50009-0 |
0.317 |
|
| 1988 |
Purvis K, Rui H. [61] High-affinity, calmodulin-dependent isoforms of cyclic nucleotide phosphodiesterase in rat testis Methods in Enzymology. 159: 675-685. PMID 2842629 DOI: 10.1016/0076-6879(88)59063-8 |
0.322 |
|
| 1987 |
Rui H, Purvis K. Prolactin selectively stimulates ornithine decarboxylase in the lateral lobe of the rat prostate. Molecular and Cellular Endocrinology. 50: 89-97. PMID 3582728 DOI: 10.1016/0303-7207(87)90080-3 |
0.315 |
|
| 1987 |
Rui H, Brekke I, Torjesen PA, Purvis K. Further observations on the autoregulation of the prolactin receptor in rat ventral prostate explants. European Journal of Endocrinology. 114: 426-432. PMID 3551431 DOI: 10.1530/Acta.0.1140426 |
0.33 |
|
| 1986 |
Rui H, Brekke I, Torjesen PA, Purvis K. Homologous up-regulation of the prolactin receptor in rat prostatic expiants Molecular and Cellular Endocrinology. 46: 53-57. PMID 3011565 DOI: 10.1016/0303-7207(86)90069-9 |
0.333 |
|
| 1986 |
Purvis K, Rui H, Gordeladze JO, Attramadal H. Hormonal activation of the adenylyl cyclases of the rat and human prostate gland The Prostate. 8: 11-24. PMID 2418428 DOI: 10.1002/Pros.2990080104 |
0.321 |
|
| 1984 |
Rui H, Gordeladze JO, Gautvik KM, Purvis K. Prolactin desensitizes the prostaglandin E1-dependent adenylyl cyclase in the rat prostate gland Molecular and Cellular Endocrinology. 38: 53-60. PMID 6542888 DOI: 10.1016/0303-7207(84)90144-8 |
0.32 |
|
| Show low-probability matches. |